ELT-001 is Elastrin Therapeutics' lead product candidate, featuring an innovative formulation of EDTA-loaded nanoparticles that are conjugated with a proprietary monoclonal antibody. This cutting-edge technology is designed to selectively target and eliminate harmful calcifications in areas where elastin has degraded, with the potential to significantly restore the elasticity of blood vessels and various organs.